查看购物车
  • Traditional Chinese
  • Japanese
视网膜疾病市场（2025）：各国疾病盛行率数据
市场调查报告书
商品编码
1928842

视网膜疾病市场（2025）：各国疾病盛行率数据

2025 Retinal Disease Model: Country-Level Disease Prevalence Data
出版日期: | 出版商: Market Scope, LLC | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

Market Scope 的 "视网膜疾病市场（2025）" 报告提供了全球视网膜疾病真实规模的详细国家层面分析。报告针对人口超过一百万的国家，按年龄组提供了详细的盛行率估算和五年预测。

此专有模型基于最新的临床研究和全球人口统计预测，提供严谨且前瞻性的视网膜疾病分析，并可根据地区和疾病类别进行定制，以满足特定的战略需求。该报告帮助企业量化潜在患者群体，评估临床和商业产品的目标市场，并了解疾病发生率和人口统计数据随时间的变化。

目录：

"视网膜疾病市场（2025）" 报告提供了228个人口超过一百万的国家/地区按年龄组划分的全面国家/地区特定患病率数据，从而全面展现了全球视网膜疾病的负担。我们的覆盖范围涵盖具有商业意义的大规模适应症，以及罕见的遗传性疾病，从而为与当前市场和未来治疗开发相关的患者群体提供统一的视角。

目标疾病包括：

  • 老年性黄斑部病变：早期AMD、晚期AMD、湿性AMD、地图状萎缩
  • 糖尿病视网膜病变：非增殖性糖尿病视网膜病变（轻度、中度、重度）、增殖性糖尿病视网膜病变（伴随或不伴随糖尿病黄斑水肿）、糖尿病黄斑水肿、威胁视力的糖尿病视网膜病变
  • 视网膜血管疾病：中心视网膜静脉阻塞与视网膜静脉分支阻塞
  • 其他视网膜疾病：近视性脉络膜新生血管、非感染性后葡萄膜炎、视网膜剥离、视网膜裂孔、视网膜分隔符
  • 遗传性视网膜疾病：视网膜色素变性、斯塔加特氏症、脉络膜色素变性、莱伯先天性黑蒙、莱伯遗传性视神经病变、全色盲、X连锁青少年视网膜劈裂症及其他遗传性视网膜疾病

研究方法：

Market Scope 利用专有的人口统计模型和最新的临床研究来估算各国的疾病盛行率。我们的视网膜疾病模型整合了来自 130 多项同行评审的临床和流行病学研究的数据，每项输入都经过仔细评估，并根据研究设计、样本量、年龄分层、地理相关性和范围进行加权。这些数据与特定国家的人口结构和人口预测相一致，从而在不同市场中产生一致且可比较的盛行率估计值。

简介目录

Market Scope's "2025 Retinal Disease Model" delivers deep, country-level insight into the true scale of retinal disease worldwide, with detailed prevalence estimates and five-year forecasts by age group for every country with a population over one million.

Built on the latest clinical research and global demographic projections, this proprietary model provides a rigorous, forward-looking view of retinal disease-and can be customized by geography and disease category to match specific strategic needs. The model enables companies to quantify addressable patient populations, evaluate target markets for clinical- and commercial-stage products, and understand how disease volume and demographics are expected to evolve over time.

Contents:

The "2025 Retinal Disease Model" provides comprehensive, country-level prevalence data by age group across 228 countries with populations over one million, capturing the full global burden of retinal disease. Coverage spans large, commercially significant indications as well as rare inherited conditions, giving a unified view of patient populations relevant to both current markets and future therapeutic development.

Conditions covered include:

  • Age-related macular degeneration: early AMD, late AMD, wet AMD, and geographic atrophy
  • Diabetic retinal disease: non-proliferative DR (mild, moderate, severe), proliferative DR (with and without DME), diabetic macular edema, and vision-threatening DR
  • Retinal vascular disorders: central and branch retinal vein occlusion
  • Other retinal conditions: myopic choroidal neovascularization, non-infectious posterior uveitis, retinal detachment, retinal holes, and tears
  • Inherited retinal diseases: retinitis pigmentosa, Stargardt disease, choroideremia, Leber congenital amaurosis, Leber hereditary optic neuropathy, achromatopsia, X-linked juvenile retinoschisis, and other IRDs

Methodology:

Market Scope utilizes proprietary demographic models and the latest clinical research to estimate diseased populations at the country level. The retinal disease model integrates data from more than 130 peer-reviewed clinical and epidemiologic studies, with each input carefully evaluated and weighted based on study design, sample size, age stratification, geographic relevance, and scope. These data are then aligned with country-specific population structures and demographic projections to produce consistent, comparable prevalence estimates across markets.